ORIC Pharmaceuticals, Inc. ORIC announced that it has collaborated with pharma giants Bayer BAYRY and Janssen Research & Development, LLC, a Johnson & Johnson JNJ company, to support its ongoing study evaluating pipeline candidate ORIC-944. ORIC will evaluate ORIC-944 in combination with Bayer’s Nubeqa (darolutamide), an androgen receptor (AR) inhibitor, and Johnson & Johnson’s AR inhibitor Erleada (apalutamide). ORIC-944 is a potent and selective allosteric inhibitor of polycomb repressive complex 2 (PRC2). ORIC initiated dosing of ORIC-944, in combination with darolutamide as well as apalutamide, in the first half of 2024 as part of the ongoing phase Ib trial in patients with metastatic prostate cancer. Each combination cohort includes a dose escalation and expansion portion, evaluating the combination of ORIC-944 and Nubeqa or ORIC-944 and Erleada. Per the terms of the collaborations, ORIC will continue to conduct and sponsor the ongoing phase Ib trial. Bayer and Johnson & Johnson will provide darolutamide and apalutamide, respectively, for the study. ORIC maintains full global development and commercial rights to ORIC-944. Shares of ORIC were up in after-market trading on Jul 16, following the announcement. Shares were up in pre-market trading as well. Year to date, the stock has gained 18.3% against the industry’s decline of 1%. Zacks Investment Research Image Source: Zacks Investment Research ORIC-944 was initially evaluated as a single agent in a phase Ib trial in patients with advanced prostate cancer wherein it demonstrated potential best-in-class drug properties, including clinical half-life of approximately 20 hours, robust target engagement and a favorable safety profile. ORIC’s portfolio currently does not have any approved product. Hence, in the absence of a marketed product, pipeline development remains in focus. The company’s pipeline includes ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. ORIC had earlier announced the completion of the dose escalation portion of the phase Ib study of ORIC-114 and the selection of the provisional recommended phase II doses. Another candidate in the pipeline is ORIC-533. ORIC is currently completing a phase Ib study on the candidate and plans to pursue a strategic partnership for combination studies. The company has also strengthened its cash position with a $125-million private placement financing from new and existing healthcare specialist funds in January 2024. As of Mar 31, 2024, cash, cash equivalents and investments totaled $331.5 million. ORIC expects the current cash balance to be sufficient to fund its operating plans into late 2026. Zacks Rank & Stocks to Consider ORIC currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Entrada Therapeutics TRDA, which currently carries a Zacks #1 Rank (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Entrada’s loss per share estimate for 2024 has narrowed from 27 cents to 13 cents in the past 60 days, and the same for 2025 has narrowed from $3.44 to $3.21 in the past 30 days. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ):Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY):Free Stock Analysis Report Oric Pharmaceuticals, Inc. (ORIC):Free Stock Analysis Report Entrada Therapeutics, Inc. (TRDA):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...